The new CyPass ultra system has been developed to streamline the process of loading the MIGS device.

CyPass system enables to decrease the multiple steps required to implant the CyPass micro-stent, helping to maintain consistent and long-term intraocular pressure (IOP) control.

Alcon’s new ultra system features a pre-loaded CyPass micro-stent, which is placed in a loader tip attached to a hand-held surgical instrument known as CyPass applier.

In 2016, Alcon secured approval from the US Food and Drug Administration (FDA) for CyPass micro-stent.

Alcon is planning to supply the new pre-loaded system to the surgeons from the next month.

The company will exhibit the CyPass ultra system, as well as present the data from CyPass micro-stent’s study at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting this year.

Alcon North America region president Sergio Duplan said: “The introduction of the new CyPass Ultra System shows our commitment to partner with surgeons and continuously innovate in the surgical glaucoma space to ensure our technology delivers the best surgical experience possible.

“This new pre-loaded system makes it easier for surgeons to deliver optimal outcomes for their glaucoma patients undergoing cataract surgery.”

CyPass micro-stent is a prescription medical device indicated for use in conjunction with cataract surgery to reduce IOP in adult patients with mild-to-moderate primary open-angle glaucoma.

According to Alcon, the use of CyPass micro-stent is contraindicated in eyes with angle closure glaucoma and eyes with traumatic, malignant, uveitic or neovascular glaucoma or discernible congenital anomalies of the anterior chamber angle.

In October 2017, Alcon introduced new Clareon intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ECRS) congress in Portugal.

Clareon IOL, which is developed by using an advanced optic material, is delivered through an automated, disposable and pre-loaded delivery system.

Image: Novartis headquarters in Basel, Switzerland. Photo: courtesy of Novartis AG.